GGrantIndex
← Leaderboards

Yuanpu Peter Di

University Of Pittsburgh At Pittsburgh

$9,824,961
Attributed
$13,597,533
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.1M · FY200825
$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,597,533 · 8

By mechanism

R01$12,503,947 · 5
R56$616,411 · 1
K22$292,800 · 1
R21$184,375 · 1

Top collaborators

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Others in their field

Top investigators on “Lung

Research focus

LungBacteriaEpithelial CellsInfectionMediatingPredispositionIn VivoPathogenProteinsAntimicrobialAirway EpitheliumUnited StatesHost DefenseRespiratory Tract InfectionsIncidenceAntibiotic ResistanceProgramsPeptidesLiquid SubstanceIn VitroAntimicrobial DrugCellsPseudomonas AeruginosaBacterial Infections

Grant awards (28)

Airway Innate Immune Responses to Coccidioides Infection$3,075,549
R01 · FY2025 · AI
Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms$840,040
R01 · FY2025 · AI · contact PI
Optimization of a novel antimicrobial for pulmonary delivery to fight respiratory infections$184,375
R21 · FY2025 · AI · contact PI
Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms$867,033
R01 · FY2024 · AI · contact PI
Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms$880,743
R01 · FY2023 · AI · contact PI
Cellular and molecular mechanisms of e-cigarette vaping-induced acute lung injury$616,411
R56 · FY2022 · HL · contact PI
Novel antimicrobial agents to overcome antibiotic resistant Pseudomonas and MRSA respiratory infection$524,705
R01 · FY2021 · AI · contact PI
Novel antimicrobial agents to overcome antibiotic resistant Pseudomonas and MRSA respiratory infection$525,483
R01 · FY2020 · AI · contact PI
Novel antimicrobial agents to overcome antibiotic resistant Pseudomonas and MRSA respiratory infection$526,238
R01 · FY2019 · AI · contact PI
Novel antimicrobial agents to overcome antibiotic resistant Pseudomonas and MRSA respiratory infection$526,238
R01 · FY2018 · AI · contact PI
SPLUNC1 in Severe Asthma$490,516
R01 · FY2018 · HL · contact PI
Novel antimicrobial agents to overcome antibiotic resistant Pseudomonas and MRSA respiratory infection$538,447
R01 · FY2017 · AI · contact PI
SPLUNC1 in Severe Asthma$490,516
R01 · FY2017 · HL · contact PI
SPLUNC1 in Severe Asthma$490,516
R01 · FY2016 · HL · contact PI
SPLUNC1 in Severe Asthma$44,401
R01 · FY2016 · HL · contact PI
SPLUNC1 in Severe Asthma$405,084
R01 · FY2015 · HL · contact PI
Epithelial PLUNC as a determinant of Airway Mucosal Antimicrobial Activity$392,962
R01 · FY2012 · HL · contact PI
Epithelial PLUNC as a determinant of Airway Mucosal Antimicrobial Activity$398,446
R01 · FY2011 · HL · contact PI
Epithelial PLUNC as a determinant of Airway Mucosal Antimicrobial Activity$58,412
R01 · FY2011 · HL · contact PI
Epithelial PLUNC as a determinant of Airway Mucosal Antimicrobial Activity$3,457
R01 · FY2011 · HL · contact PI
Epithelial PLUNC as a determinant of Airway Mucosal Antimicrobial Activity$373,600
R01 · FY2010 · HL · contact PI
Epithelial PLUNC as a determinant of Airway Mucosal Antimicrobial Activity$57,990
R01 · FY2010 · HL · contact PI
Epithelial PLUNC as a determinant of Airway Mucosal Antimicrobial Activity$373,600
R01 · FY2009 · HL · contact PI
Epithelial PLUNC as a determinant of Airway Mucosal Antimicrobial Activity$246,371
R01 · FY2009 · HL · contact PI
Epithelial PLUNC as a determinant of Airway Mucosal Antimicrobial Activity$373,600
R01 · FY2008 · HL · contact PI
Effects of Tobacco Smoke on Airway Bactericidal Activity$108,000
K22 · FY2004 · ES
Effects of Tobacco Smoke on Airway Bactericidal Activity$108,000
K22 · FY2003 · ES
Effects of Tobacco Smoke on Airway Bactericidal Activity$76,800
K22 · FY2002 · ES